Ribosome profiling:
Unlocking the translational landscape

OHMX.bio stands as a global leader in ribosome profiling (RIBO-seq), offering cutting-edge solutions that provide unparalleled insights into the dynamics of protein synthesis. Our proprietary, high-performance pipeline and deep scientific expertise enable researchers to move beyond transcriptomics, directly observing the translational landscape with exceptional precision and reliability. We are committed to delivering the most accurate and insightful translatomics data to accelerate your discoveries across all areas of life science research.

What is Ribosome profiling?

Ribosome profiling (RIBO-seq) is a powerful next-generation sequencing technique that captures ribosome-protected mRNA fragments (RPFs). By precisely mapping the positions of active ribosomes on mRNA molecules, RIBO-seq offers a real-time, genome-wide snapshot of translation. This innovative technology bridges the critical gap between mRNA abundance (transcriptomics) and protein expression (proteomics), revealing crucial regulatory mechanisms that cannot be discerned from RNA sequencing alone, such as translational control, ribosome occupancy, and the identification of novel open reading frames (ORFs).

The OHMX.bio advantage: Unparalleled precision and insight

Our world-renowned expertise in ribosome profiling is built upon a foundation of proprietary methodologies and a relentless commitment to scientific excellence:

Superior Methodology

OHMX.bio utilizes a proprietary, high-performance pipeline meticulously optimized for RIBO-seq. This includes an industry-leading rRNA depletion strategy that ensures the highest signal-to-noise ratio, providing the most precise and reliable translatomics data available.

Tailored Solutions for Diverse Research Objectives

We offer distinct RIBO-seq solutions designed to address specific scientific questions:

Unparalleled Bioinformatics Expertise

Our services are complemented by two advanced bioinformatics packages, each meticulously tailored to support our RIBO-seq pipelines. With years of experience handling diverse data types and visualizations, our team ensures accurate, reproducible results and helps you extract the most value from your sequencing data, delivering high-quality interpretations for informed decision-making.

Broad Sample Compatibility

OHMX.bio has successfully optimized its ribosome profiling protocols across a wide range of challenging sample types, including various cell lines (adherent and suspension), diverse tissue samples (frozen and fresh), liquid biopsies, and even plant-derived samples. We provide detailed guidelines for sample preparation, including ribosomal stalling protocols, to guarantee high-quality RPF isolation.

OHMX.bio - Innovative omics solutions
OHMX.bio_Innovative omics solutions_Scientific Excellence

Applications across all types of research

Ribosome profiling offers transformative insights across a vast array of research fields, making it an indispensable tool for understanding gene expression and its regulation:

Disease Mechanisms

Uncover translational dysregulation in conditions such as cancer, neurodegenerative disorders, and metabolic diseases.

Drug Development

Evaluate gene expression changes in response to drug candidates at the translational level, aiding in mechanism-of-action studies and identifying novel therapeutic targets.

Biomarker Discovery

Identify novel translation-based biomarkers for disease diagnostics, prognosis, and patient stratification.

Translational Control

Gain deep insights into how translation is regulated, including the roles of microRNAs, RNA-binding proteins, and various initiation and termination mechanisms.

Functional Genomics

Precisely define protein-coding regions and discover novel peptides, expanding the functional annotation of genomes.

Case studies

Case study 1: Decoding sites of RNA translation in normal and cancerous tissues

Understanding the precise locations of active RNA translation is critical for deciphering gene regulation and identifying potential therapeutic targets, especially in complex diseases like cancer.
In a groundbreaking study titled “Deep learning to decode sites of RNA translation in normal and cancerous tissues” (Clauwaert, J., McVey, Z., Gupta, R. et al., Nat Commun 16, 1275 (2025)), OHMX.bio played a pivotal role in advancing this understanding. This research leveraged deep learning approaches combined with RIBO-seq data to accurately map translation initiation sites and identify actively translated regions across various tissues. The study provided unprecedented resolution into the translational landscape, revealing distinct patterns in cancerous versus normal tissues. This capability is vital for identifying novel cancer-specific translational signatures, understanding how tumors hijack translational machinery, and ultimately, for developing new therapeutic strategies that target these mechanisms. OHMX.bio’s expertise in generating high-quality RIBO-seq data was instrumental in enabling the sophisticated computational analyses that led to these significant findings.

Case study 2: Characterization of shared neoantigens in mismatch repair deficient endometrial cancer

Neoantigens, unique peptides presented on the surface of cancer cells, are crucial targets for cancer immunotherapies. Their accurate identification is paramount for developing effective personalized treatments.
In the study “Characterization of shared neoantigens landscape in Mismatch Repair Deficient Endometrial Cancer” (De Paolis, E., Nero, C., Micarelli, E. et al., npj Precis. Onc. 8, 283 (2024), DOI: 10.1038/s41698-024-00779-4), OHMX.bio’s ribosome profiling expertise contributed significantly to characterizing the neoantigen landscape in Mismatch Repair Deficient (MMRd) Endometrial Cancer. By combining genomic data with RIBO-seq, the researchers were able to identify actively translated neoantigens, providing a more refined list of immunogenic targets compared to predictions based solely on DNA or RNA sequencing. This is because RIBO-seq directly confirms which mutated sequences are actually being translated into proteins that can be presented to the immune system. This study underscores the power of RIBO-seq in the field of immuno-oncology, enabling the precise identification of shared neoantigens that could be exploited for the development of novel, broadly applicable immunotherapies for patients with MMRd endometrial cancer.

Partner with OHMX.bio for your translational research

With a foundation in ribosome profiling and a track record of numerous peer-reviewed publications, OHMX.bio is the trusted expert in translatomics. Our proprietary methodologies, deep bioinformatics expertise, and commitment to scientific excellence ensure that you receive the most accurate and insightful RIBO-seq data for your cutting-edge research.

Contact OHMX.bio today to discuss your ribosome profiling needs and take your translational research to the next level.
OHMX.bio_Innovative omics solutions_Tailored Personal Approach

Let’s get in touch!

Are you curious about how we can work on your -omics challenges together? Fill out the form below!
Our experts will reply within 2 working days to freely discuss your omics project.

Our publications using our cell en gene therapies

  1.